Research based pharmaceutical company Ranbaxy Laboratories has launched Absorica (Isotretinoin) Capsules, designed to treat severe recalcitrant nodular acne, in the US.
Absoricais, which is licensed from Cipher Pharmaceuticals, can be given without regards to meals.
Formulated using patented Lidose technology, the product's fasted Area under the plasma/serum/blood concentration-time curve from time zero to time t (AUC0-t) is 83% greater than that of Accutane, while both products are bioequivalent under fed conditions.
Ranbaxy Laboratories senior director Ashish Anvekar said the product is indicated in patients of 12 years of age and older with severe recalcitrant nodular acne.
"Absorica will be the flagship brand of the Ranbaxy dermatology product portfolio in the U.S," Anvekar added.
